These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer. Quintanilha JCF; Graf RP; Oxnard GR Oncologist; 2023 Mar; 28(3):e171-e174. PubMed ID: 36779536 [TBL] [Abstract][Full Text] [Related]
3. Association of RNF43 Genetic Alterations With BRAF Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466 [TBL] [Abstract][Full Text] [Related]
4. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609 [TBL] [Abstract][Full Text] [Related]
5. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
6. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961 [TBL] [Abstract][Full Text] [Related]
8. The Evolving Treatment Landscape in Tabernero J; Ros J; Élez E Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983 [TBL] [Abstract][Full Text] [Related]
10. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693 [TBL] [Abstract][Full Text] [Related]
11. Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. Wang C; Ouyang C; Cho M; Ji J; Sandhu J; Goel A; Kahn M; Fakih M Oncologist; 2021 Mar; 26(3):208-214. PubMed ID: 33230914 [TBL] [Abstract][Full Text] [Related]
12. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mao C; Liao RY; Qiu LX; Wang XW; Ding H; Chen Q Mol Biol Rep; 2011 Apr; 38(4):2219-23. PubMed ID: 20857202 [TBL] [Abstract][Full Text] [Related]
14. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107 [TBL] [Abstract][Full Text] [Related]
16. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534 [TBL] [Abstract][Full Text] [Related]
17. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240 [TBL] [Abstract][Full Text] [Related]